Johnson & Johnson’s stock rallies following FDA clearance of its OTTAVA robotic platform, shifting investor perception toward tech innovation.
Johnson & Johnson (JNJ) shares climbed after the FDA granted De Novo marketing authorization for its OTTAVA Robotic Surgical System on July 22, 2026. The approval marks the first table-integrated soft-tissue robotic platform, covering procedures like gastric bypass and gallbladder removal.
Wall Street initially overlooked JNJ’s strong earnings report, but the OTTAVA milestone prompted a sentiment shift. Analysts now view the healthcare giant as a high-tech innovator, contrasting its prior perception as a traditional pharmaceutical company.
The stock’s rally reflects growing investor recognition of JNJ’s long-term growth potential in robotic surgery, though revenue impact may take years to materialize.